Bruker Poised On Buyouts & Innovations Amid Several Woes
Zacks Investment Research | Oct 02, 2016 10:02PM ET
On Sep 28, 2016, we issued an updated research report on Billerica, MA-based Bruker Corporation (NASDAQ:BRKR) , a designer and manufacturer of proprietary life science and materials research systems and associated products. The company currently carries a Zacks Rank #3 (Hold).
Despite significant revenue decline organically in the last reported second-quarter 2016, we are encouraged by a comparatively better performance by the BioSpin group, optics and semiconductor metrology businesses.
Within BioSpin, during the first half of 2016, Bruker witnessed high demand for the NMR food screener and NMR clinical metabolomics research systems, as well as the new service and aftermarket offering called LabScape. The company also noted growing demand for the latest version of its cost-effective NMR wine screener module used to conduct comprehensive screening of high-value wine.
The company is progressing well with Preclinical imaging (PCI) too. Currently, Bruker offers advanced PCI solutions for a broad spectrum of application fields, such as cancer research, functional and anatomical neuroimaging, orthopedics, cardiac imaging and stroke models. Moreover, this division is experiencing rising customer demand for higher-strength pre-clinical magnetic resonance imaging (MRI) system.
Over the recent past, Bruker has pursued a number of strategies to improve its financial performance. These include the implementation of various productivity improvement initiatives at both BSI and BEST in an effort to streamline its operations. In the first half of 2016, Bruker closed its BioSpinRheinstetten manufacturing facility, which helped lower expenses and drive profitability. We believe all these initiatives will benefit the company’s future operating results.
Apart from this, we are also looking forward to the company’s MALDI PharmaPulse label-free ultra-high throughput screening platform for direct discovery on Rapiflex mass-spec system, which should fetch good orders by pharma companies in the second half of the year.
Additionally, the company's recent decision to acquire Oncovision’s preclinical PET imaging business is expected to be a strategic upside. We note that Oncovision is a leading provider of innovative medical imaging devices and applications for cancer diagnosis.
On the flip side, currency fluctuations continue to remain a drag on Bruker’s overall financial performance. The company’s weak cash balance as well as continued softness in NANO Group disappoints us. Competitive headwinds also continue to pose threats.
Key Picks from the Sector
Some top-ranked medical stocks are Align Technology Inc. (NASDAQ:ALGN) , Derma Sciences Inc. (NASDAQ:DSCI) and Antares Pharma Inc. (NASDAQ:ATRS) . All the three stocks carry a Zacks Rank #2 (Buy). You can see Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.